Alaunos Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 7, 2023
Alaunos Therapeutics (TCRT) announced it will disclose its financial results for Q4 and full year 2022 on March 7, 2023, before U.S. market opening. A conference call is scheduled for 8:30 a.m. ET to discuss results and offer corporate updates. The company focuses on T-cell receptor (TCR) cell therapy aimed at solid tumors, with ongoing Phase 1/2 trials targeting six types of cancer. Alaunos utilizes proprietary platforms for TCR development and collaborates with the National Cancer Institute to advance TCR therapy.
- Ongoing Phase 1/2 trial of TCR-T product candidates across six solid cancers.
- Strong proprietary platforms: non-viral Sleeping Beauty cell engineering and hunTR discovery platform.
- None.
HOUSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2022, on Tuesday, March 7, 2023, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:30 a.m. ET to review the financial results and provide a corporate update.
Register for the live webcast using the link here or by visiting the “Investors” section of the Alaunos website at www.alaunos.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. The event will be archived on the Company’s website for approximately 30 days after the call.
About Alaunos Therapeutics, Inc.
Alaunos Therapeutics is a leader in the science of T-cell receptor (TCR) cell therapy working to revolutionize solid cancer treatment and outcomes. The clinical-stage company’s TCR T-cell therapy (TCR-T) is one of the most advanced TCR programs targeting driver mutations in solid tumors with an ongoing Phase 1/2 trial of its TCR-T product candidates across six solid cancers. Alaunos is powered by two proprietary platforms: its elegantly efficient non-viral Sleeping Beauty cell engineering platform; and its hunTR® discovery platform, which is expanding its industry-leading library of TCRs against high-frequency driver mutations. Alaunos is a part of an ongoing collaboration with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), working to advance the science of TCR therapy. For more information, visit www.alaunos.com.
Investor Relations Contact:
Alex Lobo
Stern Investor Relations
Alex.lobo@sternir.com
Media Contact:
Heather Anderson
6 Degrees PR
handerson@6degreespr.com
FAQ
When is Alaunos Therapeutics going to report its financial results for Q4 2022?
What will Alaunos Therapeutics discuss in the conference call on March 7, 2023?
What is the focus of Alaunos Therapeutics?
